転移性大腸がん治療薬市場- 世界の産業規模、シェア、動向、機会、予測、薬剤クラス別、流通チャネル別、地域別、競合別、2020-2030F

転移性大腸がん治療薬の世界市場規模は2024年に34億米ドルとなり、2030年までの予測期間のCAGRは4.45%で、着実な成長が予測されています。

世界の転移性大腸がん治療薬市場は、より広範ながん領域の製薬業界において、ダイナミックかつ重要なセグメントです。転移性大腸がん治療薬（mCRC）は、結腸や直腸から体内の他の部位、特に肝臓や肺へのがん細胞の転移を特徴とする壊滅的な疾患です。この市場は、治療アプローチ、診断方法、治療薬の絶え間ない革新によって特徴付けられ、患者の転帰と全生存率の改善に努めています。この市場の成長促進要因のひとつは、特に高齢化が進む先進国において、世界的に大腸がんの罹患率が上昇していることです。早期診断と標的治療、免疫療法、併用治療の進歩は、mCRCの管理に革命をもたらし、効果的で個別化された治療オプションに対する需要の高まりにつながっています。製薬会社はこの分野における研究開発の最前線にあり、臨床試験や創薬に多額の投資を行い、有効性が向上し副作用の少ない新規治療法の導入を目指しています。モノクローナル抗体、チロシンキナーゼ阻害剤、免疫療法は、mCRCの治療で注目されている革新的なアプローチの一部です。

市場促進要因

大腸がん罹患率の上昇と人口の高齢化

主な市場課題

晩期診断

主要市場動向

免疫療法の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の転移性大腸がん治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤クラス別（抗 EGFR（上皮成長因子受容体）阻害剤、抗 VEGF（血管内皮成長因子）療法、抗 HER2（ヒト上皮成長因子受容体2）療法、免疫チェックポイント阻害剤、その他）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 薬剤クラス別
  • 流通チャネル別
  • 地域別

第5章 アジア太平洋地域の転移性大腸がん治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤クラス別
  • 流通チャネル別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の転移性大腸がん治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の転移性大腸がん治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の転移性大腸がん治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの転移性大腸がん治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の転移性大腸がん治療薬市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Amgen Inc.
• EMD Serono
• Eli Lilly and company
• Genentech Inc.
• Novartis AG
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Sanofi SA
• Suzhou Zelgen Biopharmaceuticals
• Taiho Oncology

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Metastatic Colorectal Cancer Drugs Market was valued at USD 3.40 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 4.45% through 2030. The Global Metastatic Colorectal Cancer Drugs Market represents a dynamic and critical segment within the broader oncology pharmaceutical industry. Metastatic Colorectal Cancer Drugs (mCRC) is a devastating condition characterized by the spread of cancerous cells from the colon or rectum to other parts of the body, most commonly the liver and lungs. This market is marked by constant innovation in treatment approaches, diagnostic methods, and therapeutic agents, as it strives to improve patient outcomes and overall survival rates. One of the key drivers of growth in this market is the rising incidence of colorectal cancer worldwide, particularly in developed nations with aging populations. Early diagnosis and advancements in targeted therapies, immunotherapies, and combination treatments have revolutionized the management of mCRC, leading to increased demand for effective and personalized treatment options. Pharmaceutical companies are at the forefront of research and development in this space, investing heavily in clinical trials and drug discovery to introduce novel therapies with improved efficacy and fewer side effects. Monoclonal antibodies, tyrosine kinase inhibitors, and immunotherapies are some of the innovative approaches that have gained prominence in the treatment of mCRC.

Key Market Drivers

Rising Incidence of Colorectal Cancer & Aging Population

The rising global incidence of colorectal cancer (CRC) is a primary driver of the Global Metastatic Colorectal Cancer (mCRC) Drugs Market. In 2020, the global colorectal cancer burden was significant, with an estimated 1.9 million newly diagnosed cases and over 930,000 fatalities attributed to the disease. These figures underscore the increasing prevalence and mortality rate of colorectal cancer, highlighting the urgent demand for advanced treatment solutions and expanded healthcare interventions in both developed and emerging markets. As the number of diagnosed cases continues to escalate, the demand for advanced treatment options, innovative drug therapies, and improved patient care solutions is rising. This trend is creating significant business opportunities for pharmaceutical companies, biotech firms, and healthcare providers.

Key Market Challenges

Late-stage Diagnosis

Metastatic Colorectal Cancer Drugs begins as colorectal cancer but progresses to a stage where cancer cells have spread to other parts of the body, such as the liver, lungs, or distant lymph nodes. The problem often starts with late-stage diagnosis, where patients do not exhibit symptoms until the disease has already advanced.

Several factors contribute to the late-stage diagnosis of mCRC. One key factor is the lack of routine screening and awareness. Unlike breast or prostate cancer, colorectal cancer lacks widespread routine screening programs, leading to delayed detection. Moreover, some individuals may avoid seeking medical attention due to embarrassment or fear of invasive procedures associated with colorectal cancer screening. Healthcare disparities also play a role in late-stage diagnosis. Limited access to healthcare services, especially in underserved communities or low-income regions, can lead to delayed diagnosis and treatment initiation. Additionally, healthcare providers may not always consider colorectal cancer as a potential diagnosis, leading to misdiagnoses or delayed referrals to specialists.

Key Market Trends

Advancements in Immunotherapy

Advancements in immunotherapy have emerged as a potent force in the global Metastatic Colorectal Cancer Drugs (mCRC) market, ushering in a new era of hope and promise for patients facing this challenging disease. Immunotherapy, a groundbreaking treatment approach that harnesses the body's own immune system to target and destroy cancer cells, has begun to revolutionize the treatment landscape for mCRC.

Key immunotherapeutic agents, such as immune checkpoint inhibitors, have demonstrated remarkable efficacy in specific subsets of mCRC patients. Pembrolizumab and nivolumab, for instance, have gained FDA approval for mCRC patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. These therapies have shown the potential to induce long-lasting responses, providing new treatment options for a previously underserved patient population.

Key Market Players

• Amgen Inc.
• EMD Serono
• Eli Lilly and company
• Genentech Inc.
• Novartis AG
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Sanofi
• Suzhou Zelgen Biopharmaceuticals
• Taiho Oncology

Report Scope:

In this report, the Global Metastatic Colorectal Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metastatic Colorectal Cancer Drugs Market, By Drug Class:

• Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors
• Anti-VEGF (Vascular Endothelial Growth Factor) Therapies
• Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies
• Immune Checkpoint Inhibitors
• Others

Metastatic Colorectal Cancer Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Metastatic Colorectal Cancer Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metastatic Colorectal Cancer Drugs Market.

Available Customizations:

Global Metastatic Colorectal Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Metastatic Colorectal Cancer Drugs Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Drug Class (Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors, Anti-VEGF (Vascular Endothelial Growth Factor) Therapies, Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies, Immune Checkpoint Inhibitors, Others)
  • 4.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.3. By Region
  • 4.2.4. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Drug Class
  • 4.3.2. By Distribution Channel
  • 4.3.3. By Region

5. Asia Pacific Metastatic Colorectal Cancer Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class
  • 5.2.2. By Distribution Channel
  • 5.2.3. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Metastatic Colorectal Cancer Drugs Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Drug Class
      • 5.3.1.2.2. By Distribution Channel
  • 5.3.2. India Metastatic Colorectal Cancer Drugs Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Drug Class
      • 5.3.2.2.2. By Distribution Channel
  • 5.3.3. Australia Metastatic Colorectal Cancer Drugs Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Drug Class
      • 5.3.3.2.2. By Distribution Channel
  • 5.3.4. Japan Metastatic Colorectal Cancer Drugs Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Drug Class
      • 5.3.4.2.2. By Distribution Channel
  • 5.3.5. South Korea Metastatic Colorectal Cancer Drugs Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Drug Class
      • 5.3.5.2.2. By Distribution Channel

6. Europe Metastatic Colorectal Cancer Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Metastatic Colorectal Cancer Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Germany Metastatic Colorectal Cancer Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Spain Metastatic Colorectal Cancer Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Distribution Channel
  • 6.3.4. Italy Metastatic Colorectal Cancer Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Class
      • 6.3.4.2.2. By Distribution Channel
  • 6.3.5. United Kingdom Metastatic Colorectal Cancer Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Class
      • 6.3.5.2.2. By Distribution Channel

7. North America Metastatic Colorectal Cancer Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Metastatic Colorectal Cancer Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. Mexico Metastatic Colorectal Cancer Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. Canada Metastatic Colorectal Cancer Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Distribution Channel

8. South America Metastatic Colorectal Cancer Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Metastatic Colorectal Cancer Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. Argentina Metastatic Colorectal Cancer Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Colombia Metastatic Colorectal Cancer Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Distribution Channel

9. Middle East and Africa Metastatic Colorectal Cancer Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Metastatic Colorectal Cancer Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. Saudi Arabia Metastatic Colorectal Cancer Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. UAE Metastatic Colorectal Cancer Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Distribution Channel
  • 9.3.4. Egypt Metastatic Colorectal Cancer Drugs Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Drug Class
      • 9.3.4.2.2. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Metastatic Colorectal Cancer Drugs Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Amgen Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. EMD Serono
• 14.3. Eli Lilly and company
• 14.4. Genentech Inc.
• 14.5. Novartis AG
• 14.6. Pfizer Inc.
• 14.7. F. Hoffmann-La Roche Ltd
• 14.8. Sanofi SA
• 14.9. Suzhou Zelgen Biopharmaceuticals
• 14.10. Taiho Oncology

15. Strategic Recommendations

16. About Us & Disclaimer